People / Staff

Jaume Mora Graupera

Search publications

Publications

  • Johann PD, Erkek S, Zapatka M, Kerl K, Buchhalter I, Hovestadt V, Jones DT, Sturm D, Hermann C, Segura Wang M, Korshunov A, Rhyzova M, Gröbner S, Brabetz S, Chavez L, Bens S, Gröschel S, Kratochwil F, Wittmann A, Sieber L, Geörg C, Wolf S, Beck K, Oyen F, Capper D, van Sluis P, Volckmann R, Koster J, Versteeg R, von Deimling A, Milde T, Witt O, Kulozik AE, Ebinger M, Shalaby T, Grotzer M, Sumerauer D, Zamecnik J, Mora J, Jabado N, Taylor MD, Huang A, Aronica E, Bertoni A, Radlwimmer B, Pietsch T, Schüller U, Schneppenheim R, Northcott PA, Korbel JO, Siebert R, Frühwald MC, Lichter P, Eils R, Gajjar A, Hasselblatt M, Pfister SM and Kool M.

    Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes

    Cancer Cell . 29(3): 379-393. Number of citations: 401

    [doi:10.1016/j.ccell.2016.02.001]

  • Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grünewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Radic Sarikas B, Rédini F, Richter GH, Rossig C, Schadler K, Schäfer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Szuhai K, Tirado OM, Tirode F, Toretsky J, Tsafou K, Üren A, Zinovyev A and Delattre O.

    The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease

    Oncotarget . 7(8): 8613-8624. Number of citations: 33

    [doi:10.18632/oncotarget.6937]

  • Monterrubio C, Pascual-Pastó G, Cano F, Vilà-Ubach M, Manzanares-Quintela A, Schaiquevich P, Tornero JA, Sosnik A, Mora J and Carcaboso AM.

    SN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgery

    Biomaterials . 79: 69-78. Number of citations: 40

    [doi:10.1016/j.biomaterials.2015.11.055]

  • Rosé A, André N, Rozados VR, Mainetti LE, Márquez MM, Rico MJ, Schaiquevich P, Villarroel M, Gregianin L, Mora J, García WG, Epelman S, Alasino C, Alonso D, Chantada G and Scharovsky OG.

    Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27-28 May, 2016, Rosario, Argentina.

    ecancermedicalscience . 10: 672-672. Number of citations: 10

    [doi:10.3332/ecancer.2016.672]

  • Mora J, Suñol M, Rodriguez E and de Torres C.

    Vascular tumors preceding Ewing sarcoma: clinico-pathological observations

    Sarcoma Research International . 2(3): 1021.

  • Garzón M, García-Fructuoso G, Suñol M, Mora J and Cruz-Martínez O.

    Low-grade gliomas in children: single institutional experience in 198 cases

    CHILDS NERVOUS SYSTEM . 31(9): 1447-1459. Number of citations: 8

    [doi:10.1007/s00381-015-2800-9]

  • Monterrubio C, Paco-Mercader S, Vilà-Ubach M, Rodriguez E, Glisoni R, Lavarino C, Schaiquevich P, Sosnik A, Mora J and Carcaboso AM.

    Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts

    PHARMACEUTICAL RESEARCH . 32(9): 2889-2900. Number of citations: 10

    [doi:10.1007/s11095-015-1671-9]

  • Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, Del Carmen García-Macías M, Sevillano V, Alonso D, Pascual-Pastó G, San-Segundo L, Vilà-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J and de Álava E.

    The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

    Oncotarget . 6(22): 18875-18890. Number of citations: 64

    [doi:10.18632/oncotarget.4303]

  • Mora J, Cruz-Martínez O, Lavarino C, Rios J, Vancells M, Parareda A, Salvador-Hernandez H, Suñol M, Carrasco-Torrents R, Guillen-Quesada A, Mañé S and de Torres C.

    Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7)

    CLINICAL & TRANSLATIONAL ONCOLOGY . 17(7): 521-529. Number of citations: 12

    [doi:10.1007/s12094-014-1273-8]

  • Brosa M, García Del Muro X, Mora J, Villacampa A, Pozo-Rubio T, Luaces-Cubells C and Montoto C.

    Orphan drugs revisited: cost-effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma

    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH . 15(2): 331-340. Number of citations: 8

    [doi:10.1586/14737167.2015.972378]